Wall Street · NY Daily Wire
Oral GLP‐1 weight loss drugs have moved from niche science to front‐page finance, with big pharma and biotechs racing to tap a market projected near US$100b a year. Convenience pills are challenging injectables and reshaping expectations around obesity treatment, which creates both promise and risk for investors trying to keep up. This article walks through 3 stocks exposed to this news wave and explains why each might deserve a closer look now.
The three stocks below are just a starting sample, and the full screen surfaced 7 more oral GLP‐1 and pill based obesity developers with equally compelling narratives that are not covered here. To go deeper into this theme, head straight into the Oral Weight-Loss (GLP‐1) Drug Developers screener to identify, compare, and analyze the highest conviction plays in this sector. Hua Medicine (Shanghai) (SEHK:2552) Hua Medicine (Shanghai) sits close to the oral GLP‐1 weight loss theme through its focus on diabetes and metabolic drugs.
This gives investors exposure to treatments that can plug into the obesity pill story without being a pure GLP‐1 player. Hua Medicine generates about CN¥654 million from pharmaceuticals in China and has a market cap near HK$2.1 billion. This is a mid sized specialist with one commercial pillar and pipeline add ons that tie back to glucose control and obesity combinations.
"Although Hua Medicine highlights an extended patent life for dorzagliatin and stable NRDL pricing through 2027, a single drug exposed to a crowded type 2 diabetes market can still see pressure on future prescribing and leave group revenue highly sensitive to any change in formulary status or competing therapies, which could cap revenue growth and strain gross margins." This raises the question of what happens if a relatively quiet shift in this competitive mix affects either prescribing patterns or future pricing power. That concentration risk is exactly why reading the full narrative for Hua Medicine (Shanghai) can help you see whether dorzagliatin is masking upside or stalling Hua Medicine’s GLP-1 adjacent ambitions. SEHK:2552 Earnings & Revenue History as at Oct 2026 Shilpa Medicare (BSE:530549) Shilpa Medicare plugs into the oral GLP‐1 story from the manufacturing side, supplying APIs, finished formulations, and CDMO work that can support pill based obesity drugs as volumes rise globally.
Shilpa Medicare generates about ₹16.8b from pharmaceuticals and, with a market cap near ₹183.4b, combines a sizeable manufacturing base with exposure to GLP‐1 related peptide and oral dosage work. For investors following the surge in oral obesity treatments, Shilpa Medicare offers a different angle by focusing on the nuts and bolts of production rather than chasing a single headline pill. "Escalating global regulatory scrutiny, especially in the US and Europe, poses a significant risk of delayed product approvals, higher ongoing compliance costs, and makes successful expansion for Shilpa Medicare's extensive pipeline far less certain." What really matters next is how one pressure on its GLP‐1 manufacturing plans ultimately filters through to margins and long term earnings power.
If that pressure point is what you are watching, the full narrative for Shilpa Medicare shows how Shilpa Medicare’s regulatory risk and GLP‐1 exposure could be decoupling from the headline story. BSE:530549 Revenue & Expenses Breakdown as at Oct 2026 Protagonist Therapeutics (PTGX) Protagonist Therapeutics gives you exposure to the oral peptide side of the obesity and GLP‐1 story, pairing a discovery engine focused on oral and injectable peptides with a broader immune and blood disorder portfolio that already throws off royalty income and funds further development work. Protagonist Therapeutics generated about US$282 million from biotechnology activities, all from the United States, and carries a roughly US$8.8b market cap, which puts real financial weight behind its oral peptide pipeline and obesity focused candidates.
"Growing ICOTYDE prescription volumes, tiered global royalties of 6 to 10% and up to US$580 million of remaining sales milestones create operating leverage as the oral peptide gains share in plaque psoriasis. This could have a direct effect on Protagonist Therapeutics royalty revenue and earnings over time." What happens if a single assumption about how quickly those next oral peptide programs scale proves either too cautious or too optimistic for margins? That inflection point is exactly what the full narrative for Protagonist Therapeutics unpacks, showing where Protagonist Therapeutics royalty engine could be accelerating or quietly masking bigger obesity upside.
NasdaqGM:PTGX Earnings & Revenue History as at Oct 2026 Seeking Alternatives Before The Crowd Moves Fresh themes can move from quiet to flying fast, and the strongest ideas rarely stay under the radar for long. Scan these curated sets before momentum gets away and consider them early. Shift your focus toward resilient balance sheets and steady fundamentals by reviewing a curated list of solid balance sheet and fundamentals (203 results) that helps you sidestep fragile stories while it still matters.
Review structural demand in power and grid upgrades with a targeted pool of 41 power grid technology and infrastructure stocks that could benefit as infrastructure spending builds, and assess them on your own schedule. Zero in on high conviction 618 high quality undiscovered gems before wider attention arrives and valuations reset, giving you a clearer view of quality while expectations remain contained. This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. New: Manage All Your Stock Portfolios in One Place We've created the ultimate portfolio companion for stock investors, and it's free. • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free Have feedback on this article?
Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Source: Simply Wall Street
